Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders
Pacira BioSciences has filed its definitive proxy statement and urges shareholders to vote 'FOR' its three board nominees (Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans) on the BLUE proxy card, opposing the slate put forth by activist investor DOMA Perpetual Capital Management. The company highlighted significant progress under its '5x30 strategy', noting the stock is up over 35% since its launch and that it has returned $200 million to shareholders via buybacks since 2025, reducing shares outstanding from 47 million to 39 million.
Key figures
- Revenue
- $ 726,411
- Patients treated 2025
- 2.5 million
- Share repurchases 2025
- $150 million
- Share reduction millions
- 8
- Exparel volume growth 2025
- 6.2%
- Gaap gross margin pct 2025
- 79.4%
- Share repurchases 2026 ytd
- $50 million
- Non gaap gross margin pct 2025
- 81.2%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.